Latest Conference Articles

‘Knowledge is Power’: Advocating for More Representation in Cancer-Related Clinical Trials

‘Knowledge is Power’: Advocating for More Representation in Cancer-Related Clinical Trials

February 19th 2021, 10:00pm

DONNA Foundation Marathon Weekend

There are several health equity barriers in patients with cancer, one of which involves adequate access to clinical trials. Here, a panel of experts and a cancer survivor discuss ways to improve access.

Cabometyx Significantly Prolongs Survival Over Sutent in Rare Form of Kidney Cancer

Cabometyx Significantly Prolongs Survival Over Sutent in Rare Form of Kidney Cancer

February 18th 2021, 2:00pm

ASCO Genitourinary Symposium

The study results, according to one expert, show that Cabometyx should be considered the new standard for systemic therapy in patients with metastatic papillary renal cell carcinoma.

Padcev Continues to Show Promise in Patients with Previously Treated Bladder Cancer

Padcev Continues to Show Promise in Patients with Previously Treated Bladder Cancer

February 15th 2021, 10:00pm

ASCO Genitourinary Symposium

Treatment with Padcev, compared to chemotherapy, continues to show better results in patients with advanced urothelial carcinoma who had previously received certain therapies.

Lenvima Plus Keytruda Associated With Better Results Than Sutent Alone in Patients With Advanced Type of Kidney Cancer

Lenvima Plus Keytruda Associated With Better Results Than Sutent Alone in Patients With Advanced Type of Kidney Cancer

February 13th 2021, 10:00pm

ASCO Genitourinary Symposium

The results of the phase 3 trial, according to one expert, support the use of Lenvima with Keytruda as a possible first-line treatment option for patients with advanced renal cell carcinoma.

Novel Therapy Demonstrates Limited Activity and Poor Safety Outcomes in Patients With Metastatic Renal Cell Carcinoma

Novel Therapy Demonstrates Limited Activity and Poor Safety Outcomes in Patients With Metastatic Renal Cell Carcinoma

February 13th 2021, 6:00pm

ASCO Genitourinary Symposium

Treatment with sapanisertib was associated with limited activity and poor safety outcomes in patients with refractory metastatic renal cell carcinoma.

Communication And Support Can Help Patients With Cancer Improve Their Quality of Life During Treatment

Communication And Support Can Help Patients With Cancer Improve Their Quality of Life During Treatment

February 13th 2021, 4:00pm

ASCO Genitourinary Symposium

For patients to maintain or improve their quality of life through their cancer treatment, it is pivotal that they communicate with their health care team.

New Options for Renal Cell Carcinoma Could Offer Hope, But Sequencing and a Personalized Approach Are Critical

New Options for Renal Cell Carcinoma Could Offer Hope, But Sequencing and a Personalized Approach Are Critical

February 12th 2021, 10:20pm

ASCO Genitourinary Symposium

Clinical trials remain the gold standard when it comes to finding new treatment options for patients, particularly when it comes to renal cell carcinoma. But even if the results are positive and this combination proves to be beneficial, patients should still discuss all of their options with their oncologist to find the right sequence of treatment, says one expert.

Zytiga and Prednisone Plus Erleada Reduces Risk of Disease Progression in Prostate Cancer Subtype

Zytiga and Prednisone Plus Erleada Reduces Risk of Disease Progression in Prostate Cancer Subtype

February 12th 2021, 8:45pm

ASCO Genitourinary Symposium

The combination of Erleada, Zytiga and the steroid prednisone was associated with a trend toward better survival outcomes in certain patients with chemotherapy-naive metastatic castration-resistant prostate cancer.

Opdivo-Cabometyx Combo Improves Quality of Life in Kidney Cancer Subtype

Opdivo-Cabometyx Combo Improves Quality of Life in Kidney Cancer Subtype

February 12th 2021, 6:30pm

ASCO Genitourinary Symposium

Front-line treatment with Opdivo plus Cabometyx improved health-related quality of life outcomes in patients with advanced renal cell carcinoma.

Front-Line Immunotherapy Improves Survival in Kidney Cancer Subtype, Versus Certain Targeted Therapies

Front-Line Immunotherapy Improves Survival in Kidney Cancer Subtype, Versus Certain Targeted Therapies

February 11th 2021, 9:56pm

ASCO Genitourinary Symposium

Patients with metastatic non–clear cell renal cell carcinoma who receive immune checkpoint inhibitor–based regimens as a first treatment option may have improved survival, versus those who receive select targeted therapies.